- Home
- CAES vs LCTX Comparison
CAES vs LCTX Comparison
Compare CAES & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CAES | LCTX |
|---|---|---|
| Founded | N/A | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 321.5M | 301.7M |
| IPO Year | 2026 | 1996 |
Fundamental Metrics
Financial Performance| Metric | CAES | LCTX |
|---|---|---|
| Price | $10.09 | $1.11 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $6.25 |
| AVG Volume (30 Days) | 22.2K | ★ 802.4K |
| Earning Date | N/A | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $14,556,000.00 |
| Revenue This Year | N/A | $109.40 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 53.24 |
| 52 Week Low | $10.05 | $1.00 |
| 52 Week High | $10.12 | $2.09 |
Technical Indicators
Market Signals| Indicator | CAES | LCTX |
|---|---|---|
| Relative Strength Index (RSI) | 52.21 | 49.40 |
| Support Level | $10.06 | $1.02 |
| Resistance Level | $10.11 | $1.18 |
| Average True Range (ATR) | 0.01 | 0.05 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 60.00 | 48.28 |
Price Performance
Historical ComparisonAbout CAES Cantor Equity Partners VII Inc. Class A Ordinary Shares
Cantor Equity Partners VII Inc is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.
About LCTX Lineage Cell Therapeutics Inc.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON. Its programs are based on its proprietary, in-house, cell-based manufacturing platform, which it call AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and supported by its associated development, formulation, manufacturing, and delivery capabilities. The AlloSCOPE platform is a proprietary differentiation and production modality from which, a single, well-characterized pluripotent cell line can create a stable current Good Manufacturing Practice, master cell bank.